| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Lipid 15 does not have a defined pharmacological target; rather, it is a formulation component. As an ionizable amino lipid, it carries a positive charge at low pH (e.g., in endosomes), which facilitates electrostatic interaction with negatively charged nucleic acids (siRNA, mRNA) and promotes encapsulation. At physiological pH, it is neutral, reducing toxicity and prolonging circulation time. Its ionizable property enables endosomal escape of nucleic acid cargo after cellular uptake.
|
|---|---|
| ln Vitro |
In vitro, Lipid 15 is used to formulate LNPs that encapsulate mRNA, siRNA, or other nucleic acids. These LNPs demonstrate efficient cellular uptake and transfection in various cell lines, including immune cells and hepatocytes. The ionizable nature of Lipid 15 promotes endosomal escape, allowing the release of nucleic acid cargo into the cytoplasm where it can exert its function (e.g., protein expression from mRNA or gene silencing from siRNA). Lipid 15 is also used in LNPs for vaccine applications.
|
| ln Vivo |
In vivo, Lipid 15-containing LNPs have been used to deliver mRNA and other nucleic acid therapeutics in animal models. LNPs formulated with Lipid 15 show favorable biodistribution, accumulating primarily in the liver after intravenous administration, due to apolipoprotein E (ApoE) binding and subsequent uptake by hepatocytes via LDL receptors. These LNPs can be used to achieve robust protein expression (mRNA) or gene silencing (siRNA) in target tissues. Lipid 15 is a promising component for LNP-based vaccine development.
|
| Enzyme Assay |
For LNP formulation, Lipid 15 is typically combined with helper lipids (e.g., DSPC, cholesterol, and PEG-lipid) in organic solvents (ethanol) at defined molar ratios (e.g., Lipid 15 : cholesterol : DSPC : PEG-lipid = 50:38.5:10:1.5). The lipid mixture is mixed with an aqueous solution containing nucleic acid (mRNA or siRNA) at a controlled flow rate using a microfluidic device, resulting in spontaneous LNP formation. The LNPs are dialyzed against PBS to remove ethanol, and concentrated by ultrafiltration. Particle size (typically 60-120 nm), polydispersity index, and zeta potential are measured by dynamic light scattering (DLS). Encapsulation efficiency is determined using a RiboGreen assay.
|
| Cell Assay |
For in vitro transfection assays, cells (e.g., HEK293, HeLa, or primary hepatocytes) are seeded in 96-well plates and treated with LNPs containing mRNA encoding a reporter protein (e.g., luciferase or GFP). After 24-48 hours, reporter expression is quantified by bioluminescence (luciferase) or fluorescence microscopy/flow cytometry (GFP). Gene silencing is assessed using siRNA against a target gene, and knockdown is measured by qPCR or Western blot. Cytotoxicity is assessed by MTT assay.
|
| Animal Protocol |
For in vivo studies, Lipid 15-based LNPs are formulated to encapsulate mRNA or siRNA, then diluted in PBS or 10% sucrose buffer. The LNPs are administered to rodents via intravenous injection (tail vein) at doses of 0.1-5 mg/kg (based on nucleic acid content). Blood samples are collected at various time points to assess pharmacokinetics and protein expression (e.g., luciferase signal measured by IVIS imaging). Tissue distribution is assessed by measuring fluorescence (if labeled) or by quantifying nucleic acid content in organs (liver, spleen, lungs, kidneys) by qPCR. For therapeutic studies in disease models (e.g., cancer, genetic liver disease), multiple doses may be administered over days or weeks.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Lipid 15 as a free lipid are not available, as it is always formulated into LNPs. The overall PK properties of LNPs depend on the composition, size, surface charge, and PEGylation. LNP-containing ionizable lipids typically have a circulation half-life of 2-8 hours in rodents. LNPs are primarily taken up by the liver (Kupffer cells and hepatocytes) and spleen. The biodegradation of ionizable lipids occurs via ester hydrolysis, leading to clearance. The molecular weight of Lipid 15 is 789.31, with a formula of C50H96N2O4.
|
| Toxicity/Toxicokinetics |
Toxicological data for Lipid 15 alone are limited. However, ionizable lipids are generally well tolerated in vivo at the concentrations used in LNP formulations. In cell-based assays, LNPs containing Lipid 15 show minimal cytotoxicity at concentrations that achieve efficient transfection. In animal studies, LNP administration may cause mild to moderate elevations in liver enzymes (ALT/AST) and pro-inflammatory cytokines (e.g., IL-6, TNF-alpha), which are typically transient and dose-dependent. Comprehensive toxicology studies depend on the final LNP formulation.
|
| References | |
| Additional Infomation |
Lipid 15 is a research-grade compound and is not approved for clinical use. It is an ionizable amino lipid used exclusively for LNP formulation in drug delivery research. Its ionizable nature enables efficient nucleic acid encapsulation, low toxicity, and endosomal escape. Lipid 15 is primarily used in the development of mRNA vaccines and gene therapies. CAS number: 2588111-36-6. Store as a solution in ethanol or as a powder at -20degC under inert atmosphere, protected from light and moisture.
|
| Molecular Formula |
C50H96N2O4
|
|---|---|
| Molecular Weight |
789.31
|
| Exact Mass |
788.737
|
| CAS # |
2588111-36-6
|
| PubChem CID |
168355630
|
| Appearance |
Colorless to light yellow liquid
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
46
|
| Heavy Atom Count |
56
|
| Complexity |
888
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCCC(CCCCCC)C(=O)OCCCCCCCCN(CCCCCCCC/C=C\\C/C=C\\CCCCC)CCOC(=O)CCCN(C)C
|
| InChi Key |
PQFKDYPOMGYHFK-KSWDIIKGSA-N
|
| InChi Code |
InChI=1S/C50H96N2O4/c1-6-9-12-15-17-18-19-20-21-22-23-24-25-26-30-35-43-52(45-47-55-49(53)41-38-42-51(4)5)44-36-31-27-28-32-37-46-56-50(54)48(39-33-14-11-8-3)40-34-29-16-13-10-7-2/h17-18,20-21,48H,6-16,19,22-47H2,1-5H3/b18-17-,21-20-
|
| Chemical Name |
8-[2-[4-(dimethylamino)butanoyloxy]ethyl-[(9Z,12Z)-octadeca-9,12-dienyl]amino]octyl 2-hexyldecanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (126.69 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.17 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.17 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.17 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2669 mL | 6.3346 mL | 12.6693 mL | |
| 5 mM | 0.2534 mL | 1.2669 mL | 2.5339 mL | |
| 10 mM | 0.1267 mL | 0.6335 mL | 1.2669 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
